`Case 1:22-cv-02229-MKV Document 45-3 Filed 10/04/22 Page 1 of 2
`
`
`
`
`
`
`
`
`
`
`EXHIBIT C
`EXHIBIT C
`
`
`
`Case 1:22-cv-02229-MKV Document 45-3 Filed 10/04/22 Page 2 of 2
`
`BY FEDERAL EXPRESS
`Michael P. Bauer, Ph.D.
`Assistant General Counsel
`Pfizer, Inc.
`235 East 42nd Street
`New York, New York 10017
`
`October 12, 2021
`
`Re: Arbutus/Genevant LNP Technology and Intellectual Property
`
`Dear Mr. Bauer:
`
`Thank you for your October 7, 2021, email to Pete Zorn informing Genevant that BioNTech will be
`handling further discussions regarding a potential license relating to COVID-19 vaccines. We look forward
`to hearing from BioNTech.
`
`In the meantime, we believe, and notify Pfizer and BioNTech under 35 U.S.C. § 287(a), that the
`manufacture, importation, offer for sale, sale, and/or use of the Pfizer-BioNTech COVID-19 vaccine
`Comimaty® may infringe Arbutus U.S. Patent No. 11,141,378, in addition to at least the Arbutus patents
`that were identified in our November 23, 2020 letter.
`
`William H. Collier
`President and Chief Executive Officer
`Arbutus Biopharma Corporation
`701 Veterans Circle
`Warminster, Pennsylvania 18974 USA
`
`Albert Bourla, DVM, Ph.D.
`Chairman and Chief Executive Officer
`Pfizer, Inc.
`235 East 42nd Street
`New York, New York 10017 USA
`
`Doug Lankier, Esq.
`Executive Vice President, General Counsel
`Pfizer, Inc.
`235 East 42nd Street
`New York, New York 10017 USA
`
`Markus Rohrwild
`Managing Director
`Genevant Sciences GmbH
`Viaduktstrasse 8, 4051
`Basel, Switzerland
`
`Cc:
`
`Ugur Sahin
`Chief Executive Officer
`BioNTech SE
`An der Goldgrube 12
`D-5131 Mainz Germany
`
`Sierk Poetting
`Chief Financial Officer and Chief
`Operating Officer
`BioNTech SE
`Ander Goldgrube 12
`D-5 5131 Mainz Germany
`
`General Counsel
`BioNTech US Inc.
`40 Erie Street, Suite 110
`Cambridge, MA 02139 USA
`
`I 0298-00001/12998850.1
`
`